The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy
Breast Cancer Research and Treatment · 2024-06 · 205 (2) · 241-248
DOI: 10.1007/s10549-024-07247-4 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 12.02.2024. Verfasst von Raz Mutai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Neoadjuvant Therapy, Germ-Line Mutation, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebrew University of Jerusalem.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Whether germline BRCA (gBRCA) pathogenic variants (PV) affect prognosis of women with triple negative breast cancer (TNBC) and whether it has implications for treatment decisions in the neoadjuvant setting is unclear.
Methods
This is a retrospective two-center cohort study comprising all women with early stage TNBC who have completed genetic testing and were treated with neoadjuvant dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and carboplatin. All eligible patients treated between 10.2014 and 3.2020 were included. Data on clinico-pathological, pathological response, overall survival (OS) and disease-free survival (DFS) were evaluated. Differences in clinico-pathological features and outcomes were analyzed according to gBRCA status.
Results
Sixty-four women were included in the final analysis, of which 31 had gBRCA PV (gBRCA carriers) and 33 were gBRCA wild-type. Clinico-pathological characteristics were similar between both groups. The odds for pathological complete response (pCR) were significantly higher in gBRCA carriers (74.2%) compared to BRCA wild-type women (48.5%), p = 0.035. At a median follow-up of 30 months, gBRCA carriers had significantly favorable OS (HR = 8.64, 95% CI 1.08–69.21, p = 0.042). The difference in DFS did not reach statistical significance (HR = 7.4, 95% CI 0.91–60.27, p = 0.062). The favorable OS for gBRCA carriers remained significant in multivariate analysis ( p = 0.029) and was noted regardless of pathological response ( p = 0.018).
Conclusion
Compared to wild-type, gBRCA carriers with locally advanced TNBC treated with neoadjuvant chemotherapy containing carboplatin had a higher pCR rate and better outcomes. These results strengthen the contention that gBRCA status should be considered when tailoring treatment decisions in women with locally advanced TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
- Faculty of Medicine Tel-Aviv University, Tel-Aviv, Israel.
- The Oncology Institute, Meir Medical Center, Kfar Saba, Israel.
- Department of Military Medicine and "Tzameret", Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Medical Corps, Israel Defense Forces, Ramat Gan, Israel.
- Plastic Surgery Department, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University, Jerusalem, Israel.
Förderung
- Hebrew University of Jerusalem
Zitieren
APA
Mutai, R., Kuchuk, I., Goldshtein, A., Yerushalmi, R., Rotem, O., Maisel Lotan, A., Bdolah-Abram, T., Gabizon, A., & Goldvaser, H. (2024). The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 205(2), 241-248. https://doi.org/10.1007/s10549-024-07247-4
Vancouver
Mutai R, Kuchuk I, Goldshtein A, Yerushalmi R, Rotem O, Maisel Lotan A, et al. The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 2024;205(2):241-248. doi:10.1007/s10549-024-07247-4
BibTeX
@article{Mutai2024,
author = {Mutai, Raz and Kuchuk, Iryna and Goldshtein, Alexandra and Yerushalmi, Rinat and Rotem, Ofer and Maisel Lotan, Adi and Bdolah-Abram, Tali and Gabizon, Alberto and Goldvaser, Hadar},
title = {The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy},
journal = {Breast Cancer Research and Treatment},
year = {2024},
volume = {205},
number = {2},
pages = {241--248},
doi = {10.1007/s10549-024-07247-4}
}
EUVIMED